<DOC>
	<DOC>NCT00845702</DOC>
	<brief_summary>The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.</brief_summary>
	<brief_title>Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)</brief_title>
	<detailed_description>Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.</detailed_description>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
	<criteria>Male or female, aged more than 18 years, Strongly suspected of having renal arterial disease, Scheduled (or to be scheduled) to undergo arterial catheterbased Xray angiography examination, Known grade IV or V chronic kidney disease (GFR&lt;30 mL/min/1.73m²), Contraindication to MRI, Acute renal dysfunction within the 6 months preceding Dotarem®enhanced MRA examination,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Renal artery stenosis</keyword>
	<keyword>Contrast agent</keyword>
	<keyword>MRA</keyword>
</DOC>